Table 1 A user guide for the choice of miRNA biomarkers and mRNA indicators for therapeutic outcome monitoring in mouse models for muscular dystrophy.
Transcript group | miR-name mRNA name | Dysregulation in mouse models for MD | Pathological indication | Therapeutic response in the KO-Sgca mouse model | ||
|---|---|---|---|---|---|---|
Serum | muscle | Serum | Muscle | |||
DystromiRs | miR-1 | Up | Down | Damaged myofibers | Down | Up |
miR-133a | Up | Down | Down | Up | ||
miR-206 | Up | Up | Down | Down | ||
miR indicators of other pathological changes in MD | miR-21 | Up | Up | Muscle fibrosis | Down | Down |
miR-31 | Varied | Up | MPC proliferation | Varied | Down | |
miR-142-3p | Up | Up | Inflammatory infiltration | Down | Down | |
miR indicators of yet unidentified pathological changes | miR-149-5p | Up | Down | Unknown | Down | Up |
miR-193b-3p | Up | Down | Down | Up | ||
miR-378a-3p | Up | Down | Down | Up | ||
mRNA indicators | Myh8 | Up | Myofiber regeneration | Down | ||
CD11b | Up | Inflammatory infiltration | Down | |||
Col6a3 | Up | Fibrosis | Down | |||
